Neuroendocrine cancer of the prostate metastatic – Diagnostics – Overview of Information and Clinical Research

Neuroendocrine cancer of the prostate that has spread requires careful and timely diagnosis because this rare and aggressive form of prostate cancer behaves very differently from typical prostate cancer, often showing low PSA levels and not depending on hormones for growth, making early detection both challenging and crucial for treatment planning.

Introduction: Who Should Undergo Diagnostics

Understanding when to seek diagnostic testing for neuroendocrine prostate cancer is important for both patients with a new prostate diagnosis and those who have been living with prostate cancer for some time. This form of cancer represents less than 2% of all prostate cancers, making it quite uncommon, but it tends to be particularly aggressive and requires specialized attention.^[2]

Men who should consider diagnostic evaluation include those experiencing symptoms that don’t respond well to standard hormone-blocking treatments for prostate cancer. If you’ve been receiving treatment with medications like abiraterone or enzalutamide and your cancer continues to progress despite therapy, this could be a warning sign. Additionally, if your cancer spreads to unusual places such as the liver, or if you develop rapid disease progression with symptoms that seem more severe than typical prostate cancer, diagnostic testing becomes especially important.^[1]^[8]

Neuroendocrine prostate cancer can develop in two main ways. Some men are diagnosed with it from the start, which doctors call de novo disease—meaning it appears without any previous history of typical prostate cancer. However, more commonly, it develops later in men who have been living with regular prostate cancer, particularly those who have been treated with hormone-blocking therapies for advanced disease. This transformation happens as cancer cells find ways to survive treatment by changing their behavior and no longer depending on male hormones to grow.^[2]^[13]

⚠️ Important

If you have been diagnosed with advanced prostate cancer and notice that your PSA levels are unusually low or not rising as expected while your symptoms worsen, this could be an important clue. Neuroendocrine prostate cancer often shows low PSA levels even when the disease is progressing, which is very different from typical prostate cancer. Don’t hesitate to discuss this pattern with your doctor, as it may warrant additional testing.

Recent research has shown that nearly one-fifth of men with metastatic prostate cancer whose disease became resistant to hormone therapy eventually developed this aggressive neuroendocrine subtype. This is a higher number than doctors previously expected, suggesting that this condition may be more common than once thought and emphasizing the importance of appropriate diagnostic testing when warning signs appear.^[8]

Classic Diagnostic Methods

Diagnosing neuroendocrine prostate cancer can be quite challenging, and it requires careful examination by medical experts who specialize in this area. The cornerstone of diagnosis involves obtaining a sample of the tumor tissue, typically through a biopsy, which is then examined under a microscope by a specialist doctor called a pathologist. This microscopic examination is essential because neuroendocrine cancer looks distinctly different from typical prostate cancer when viewed at the cellular level.^[2]^[13]

Under the microscope, cells from neuroendocrine prostate cancer appear smaller and more crowded together compared to the larger, more spread-out appearance of typical prostate cancer cells. This visual difference is one of the key ways pathologists can distinguish between the two types. However, making this distinction requires expert review because it’s not always straightforward. In fact, approximately 1% of all cells within a normal prostate gland are naturally neuroendocrine in origin, so finding some neuroendocrine cells in a prostate sample is not unusual. What matters is determining how many of these cells are present, whether they appear abnormal or cancerous, and how they compare in number to regular prostate cancer cells.^[2]^[13]^[8]

The location where a biopsy is taken can also be important. When neuroendocrine cancer has spread beyond the prostate to other parts of the body—a situation called metastatic disease—doctors may need to sample tumors from these distant sites. Metastatic tumors can develop in bones, lymph nodes, the liver, or other soft tissues throughout the body. Research has found that the frequency of finding neuroendocrine cancer doesn’t seem to depend on which of these sites is biopsied, which means doctors have flexibility in choosing the most accessible location for sampling.^[8]

One of the most significant challenges in diagnosing this condition is that traditional blood tests used for monitoring prostate cancer may not be as helpful. Most men with typical prostate cancer have elevated levels of prostate-specific antigen (PSA) in their blood, and doctors routinely use this marker to track disease progression. However, neuroendocrine prostate cancer often shows the opposite pattern—PSA levels tend to be low or fail to rise even when the cancer is actively growing and spreading. Similarly, these tumors typically show reduced levels of other common prostate markers like prostate specific membrane antigen (PSMA), which can make diagnosis more difficult because the usual warning signs may be absent.^[1]^[8]

To help identify neuroendocrine features, pathologists use special staining techniques on the biopsy samples. These tests look for specific proteins that are markers of neuroendocrine cells. The diagnosis involves not just identifying individual neuroendocrine cells, but also assessing the overall pattern and density of these cells throughout the tumor sample. In some cases, a tumor may contain both typical prostate cancer cells and neuroendocrine cancer cells mixed together, which adds another layer of complexity to the diagnosis.^[8]

Diagnostics for Clinical Trial Qualification

When considering participation in clinical trials for neuroendocrine prostate cancer, additional diagnostic testing may be required beyond the standard evaluation. Clinical trials are research studies that test new treatments, and they often have very specific requirements about who can participate. These requirements help ensure that the treatment being studied is tested in the right group of patients and that results can be interpreted accurately.

One important aspect of qualifying for clinical trials involves confirming the diagnosis with high certainty. This typically means having a recent biopsy that clearly shows neuroendocrine features when examined under the microscope. Because this diagnosis can be challenging and requires specialized expertise, trial sponsors may require that tissue samples be reviewed by expert pathologists who have extensive experience with neuroendocrine prostate cancer. In some cases, the tissue may need to be sent to a central laboratory for confirmation before a patient can be enrolled in a study.^[10]

Genetic and molecular testing has become increasingly important for clinical trial qualification. Researchers have discovered that neuroendocrine prostate cancer has specific genetic changes that distinguish it from typical prostate cancer. Two particularly important findings involve loss of function in genes called RB1 and TP53, which normally act as tumor suppressors—meaning they help prevent cancer from developing. When these protective genes stop working properly, cells may more easily transform into the neuroendocrine type. Clinical trials focused on neuroendocrine prostate cancer may require testing for these genetic alterations as part of the screening process.^[1]^[10]

Another important molecular characteristic involves changes in how genes are turned on and off in cells, a process controlled by epigenetics. Neuroendocrine prostate cancer shows significant epigenetic changes, including overexpression of a protein called EZH2 and alterations in DNA methylation patterns. Some clinical trials may test for these markers because they can provide important information about which patients might benefit from specific types of treatment being studied in the trial.^[1]

⚠️ Important

Current medical practice doesn’t always include routine biopsy testing for every patient with advanced prostate cancer. Traditionally, doctors have recommended biopsy only for patients showing specific warning signs, such as spread to the liver. However, research suggests that neuroendocrine transformation may be more common than previously recognized, and broader testing might help identify more patients who could benefit from different treatment approaches. If you’re concerned about this possibility, discuss with your doctor whether additional biopsy testing might be appropriate for your situation.

Some clinical trials may also look for specific gene alterations related to DNA repair mechanisms. Research has found that some patients with neuroendocrine prostate cancer have alterations in homologous recombination repair genes. These patients might particularly benefit from certain types of treatments, such as PARP inhibitors, which are drugs that target cancer cells with DNA repair defects. Testing for these genetic changes may be required or recommended as part of clinical trial screening.^[11]

Clinical trials also typically require documentation of disease extent through imaging studies. This might include CT scans, bone scans, or more advanced imaging techniques like PET scans. These tests help researchers understand how far the cancer has spread and allow them to measure changes in tumor size during treatment. Because neuroendocrine prostate cancer can behave differently from typical prostate cancer, with different patterns of spread throughout the body, comprehensive imaging evaluation is particularly important for trial participation.

Blood tests beyond PSA may also be part of clinical trial screening. While PSA is often low in neuroendocrine prostate cancer, other blood markers might provide useful information. Some trials are exploring whether blood-based tests can detect genetic material from tumor cells circulating in the bloodstream, which could potentially help identify patients with neuroendocrine transformation without requiring a tissue biopsy in every case.^[10]

Prognosis and Survival Rate

Prognosis

The outlook for patients with metastatic neuroendocrine prostate cancer is generally more challenging than for those with typical prostate cancer. Several factors influence how the disease will progress, including when the diagnosis is made, how extensively the cancer has spread, and how well it responds to initial treatment. Unfortunately, the aggressive nature of this cancer type often means that it grows and spreads more quickly than regular prostate cancer.

One significant factor affecting prognosis is that this condition is often diagnosed late in the disease course. The poor prognosis of neuroendocrine prostate cancer is attributed in part to delayed diagnosis and a current lack of highly effective therapeutic agents specifically designed for this cancer type. Because the cancer often develops as a transformation from typical prostate cancer after years of hormone therapy, and because traditional monitoring tools like PSA may not show warning signs, opportunities for early intervention can be missed.^[1]

The pattern of disease spread also influences outcomes. While typical prostate cancer most commonly spreads to bones, neuroendocrine prostate cancer can spread to other organs including the liver, which generally indicates more aggressive disease. Patients whose cancer has spread to the liver or shows rapid progression at multiple sites often face more difficult treatment challenges.^[8]

Survival Rate

Studies examining survival in patients with metastatic neuroendocrine prostate cancer have shown that this subtype is associated with shorter survival times compared to typical prostate cancer. Research following men with castrate-resistant metastatic prostate cancer found important differences in survival based on tumor type. Men whose metastatic tumors consisted of typical prostate cancer cells lived a median of 44.5 months from the time their disease became resistant to hormone therapy. In contrast, men whose tumors had transformed to neuroendocrine cancer had a median survival of 36.6 months—approximately eight months shorter. Those with tumors containing both typical and neuroendocrine cells had similar survival to those with pure neuroendocrine disease, with a median of 36.8 months.^[8]

It’s important to understand that these survival statistics represent median values from research studies, meaning half of patients lived longer and half lived shorter periods. Individual outcomes can vary considerably based on many factors including overall health, age, specific genetic characteristics of the cancer, how well it responds to treatment, and access to specialized care and clinical trials. These numbers also represent past data, and ongoing research continues to explore new treatment approaches that may improve outcomes in the future.

#1 Clinical Trials Search in Europe